Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

Abstract Aim Trabectedin in combination with pegylated liposomal doxorubicin (PLD) improves progression-free survival (PFS) compared to PLD alone in recurrent ovarian cancer (J Clin Oncol 2010;28:3107–14). Methods Women, stratified by performance status (0–1 versus 2) and platinum sensitivity (plati...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2012-10, Vol.48 (15), p.2361-2368
Main Authors: Monk, Bradley J, Herzog, Thomas J, Kaye, Stanley B, Krasner, Carolyn N, Vermorken, Jan B, Muggia, Franco M, Pujade-Lauraine, Eric, Park, Youn C, Parekh, Trilok V, Poveda, Andres M
Format: Article
Language:English
Subjects:
Aged
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carcinoma, Ovarian Epithelial
Dioxoles - administration & dosage
Disease-Free Survival
Doxorubicin - administration & dosage
Doxorubicin - analogs & derivatives
Doxorubicin - therapeutic use
Female
Hematology, Oncology and Palliative Medicine
Humans
Medical sciences
Middle Aged
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial - drug therapy
Neoplasms, Glandular and Epithelial - pathology
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Pegylated liposomal doxorubicin
Pharmacology. Drug treatments
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Recurrent ovarian cancer
Survival Analysis
Tetrahydroisoquinolines - administration & dosage
Trabectedin
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aim Trabectedin in combination with pegylated liposomal doxorubicin (PLD) improves progression-free survival (PFS) compared to PLD alone in recurrent ovarian cancer (J Clin Oncol 2010;28:3107–14). Methods Women, stratified by performance status (0–1 versus 2) and platinum sensitivity (platinum-free interval [PFI]
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2012.04.001